Brainstorm Cell Therapeutics (BCLI) Q4 2021 Earnings Report

575 Followers

BCLI Q4 2021 EPS Results

Actual EPS-$1.13

Consensus EPS-$2.95

Beat/MissBeat by +$1.83

One Year Ago EPS-$5.40

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

QuarterQ4 2021

Date03/28/2022

TimeBefore Open

Conference CallMonday, March 28, 2022

BCLI Upcoming Earnings

Brainstorm Cell Therapeutics's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

No earnings call audio is available for this earnings event.

No slide deck is available for this earnings event.

No earnings call summary is available for this earnings event.

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2026 (Q3)	-0.18 / -	-0.19	―
Aug 14, 2026	2026 (Q2)	- / -0.35	-0.34	-2.94% (>-0.01)
May 15, 2026	2026 (Q1)	- / -0.19	-0.45	57.78% (+0.26)
Mar 31, 2026	2025 (Q4)	-0.28 / -0.19	-0.45	57.78% (+0.26)
Nov 14, 2025	2025 (Q3)	-0.37 / -0.19	-0.51	62.75% (+0.32)
Aug 14, 2025	2025 (Q2)	-0.37 / -0.34	0.6	-156.67% (-0.94)
May 16, 2025	2025 (Q1)	- / -0.45	-0.75	40.00% (+0.30)
Mar 31, 2025	2024 (Q4)	-0.97 / -0.45	-0.75	40.00% (+0.30)
Nov 14, 2024	2024 (Q3)	-0.57 / -0.51	-0.45	-13.33% (-0.06)
Aug 14, 2024	2024 (Q2)	-0.53 / 0.60	-1.95	130.77% (+2.55)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed